EMD Serono Announces New MAVENCLAD(r) Data Supporting Cognitive Function Benefits

Source :: Plus Company Updates. March 2, 2024
Publication Year :: 2024
Abstract: ROCKLAND: EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of two new post-hoc analyses of tertiary endpoints from the MAGNIFY-MS [...]

Subjects :: Merck KGaA
Multiple sclerosis -- Analysis
Pharmaceutical industry -- Analysis
General interest
News, opinion and commentary
Mavenclad (Medication)

Tools